WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

List of DDDs for 3 years revision

The DDDs, which will be reviewed at the March 2023 meeting (3 year revision) are listed below.  See also Guidelines: Part III; D Principles for reviewing and changing DDD and Part V; D Requests for changes to DDDs. The deadline for applications for alterations and comments is 1 February 2023.  

 

ATC codeATC level name (INN/generic name)DDDUnitAdm.route
N05CD08midazolam10mgSL
A07EA06budesonide2mgSL
N07BC01buprenorphine2.1mgP
L04AC18risankizumab1.67mgP
L04AC17tildrakizumab1.11mgP
J01DH56imipenem, cilastatin and relebactam4)gP
J01DH52meropenem and vaborbactam3)gP
B06AC05lanadelumab21.4mgP
B01AX07caplacizumab10mgP
N03AX25cenobamate0.2gO
J01MA25lascufloxacin75mgO
H05BX05calcifediol30mcgO
D01BA03fosravuconazole0.1 2)gO
B03AB10ferric maltol60mg Fe3+O
A16AX12trientine0.45 1)gO
A10BG04lobeglitazone0.5mgO
N05CD08midazolam5mgN
H04AA01glucagon3mgN
1) expressed as trientine
2) expressed as ravuconazole
3) Refers to meropenem
4) Refers to imipenem

Last updated: 2022-12-19